For treatment costs, we assumed full adherence to medications, and derived medication costs directly from the Australian Pharmaceutical Benefits Scheme ( The most common SGLT2i in Australia in 2020 was empagliflozin
Can we use old NAFLD data under the new MASLD definition
Using BioTE for Low Energy As we age, our bodies have a more challenging time keeping up biologically
Some users in community sources report sustained benefit at this stage
This could cover anything from SLU-PP-332, to retatrutide, to SS-31, to Selank or Semax
This is the evidence for a wider scope, which is why the role of the ingredient has become more prominent in this region, thereby supporting market progression